BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Li M, Kaili D, Shi L. Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. World J Gastrointest Oncol 2022; 14(1): 19-37 [PMID: 35116101 DOI: 10.4251/wjgo.v14.i1.19]
URL: https://www.wjgnet.com/1948-5182/full/v14/i1/19.htm
Number Citing Articles
1
Cheng-Lun Lai, Ming-Huang Chen. Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinomaJournal of Cancer Research and Practice 2022; 9(4): 145 doi: 10.4103/2311-3006.362634
2
A. B. Rays, М. Yu. Fedyanin, D. V. Popov, I. А. Pokataev, М. A. Lyadova, L. G. Zhukova, D. L. Stroyakovsky, М. V. Volkonsky, D. А. Gavrilova, N. S. Besova, А. А. Tryakin. Efficacy of immunotherapy in advanced gastric cancer: preliminary results of a multicenter observational studyMalignant tumours 2024;  doi: 10.18027/2224-5057-2024-006
3
Yoshiaki Shoji, Kazuo Koyanagi, Kohei Kanamori, Kohei Tajima, Mika Ogimi, Yamato Ninomiya, Miho Yamamoto, Akihito Kazuno, Kazuhito Nabeshima, Takayuki Nishi, Masaki Mori. Immunotherapy for esophageal cancer: Where are we now and where can we goWorld Journal of Gastroenterology 2024; 30(19): 2496-2501 doi: 10.3748/wjg.v30.i19.2496
4
Wan‐Yuan Ruan, Lu Zhang, Shan Lei, Zhi‐Rui Zeng, Yu‐Shi Yang, Wen‐Peng Cao, Qiu‐Yao Hao, Min Lu, Xiao‐Bin Tian, Pai‐Lan Peng. An inflammation‐associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinomaJournal of Cellular and Molecular Medicine 2023; 27(13): 1820 doi: 10.1111/jcmm.17780